GCAND — TRAFALGAR INTERNATIONAL, INC.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1695473 ·
Last close
$1.60
Market Cap
—
52W High
$3.36
52W Low
$0.18
ADV30
1,611
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | 0 | -11,555 | 611,378 | 111 | 111 | 12,239 |
| Mar 2026 | 0 | 0 | -33,376 | -33,376 | 1,439 | 1,439 | 776,464 |
| Dec 2025 | 0 | 0 | -53,806 | 337,757 | 815 | 815 | 742,464 |
| Sep 2025 | 0 | 0 | -37,412 | -36,099 | 21,355 | 21,355 | 1,129,697 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-40,701
Investing CF
$0
Financing CF
$10,500
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.14
As of
2026-09-27
Balance + Analyst (yfinance extras)
Retained Earnings
$-4,413,955
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$572,024
Pretax Income TTM
$879,660
Interest Exp TTM
$-138,021
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -183,005 | -331,612 | 815 | 742,464 | -741,649 | -60,153 |
| Dec 2024 | 0 | -156,276 | -179,041 | 57,785 | 898,058 | -840,273 | -109,491 |
| Dec 2023 | 0 | -175,364 | -188,402 | 172,276 | 833,508 | -661,232 | -103,171 |
| Dec 2022 | 0 | -177,035 | -360,268 | 280,447 | 825,277 | -544,830 | -107,490 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.03T | $1157.08 | — |
| JNJ | JOHNSON & JOHNSON | $638.00B | $264.74 | — |
| ABBV | AbbVie Inc. | $462.26B | $261.59 | — |
| MRK | Merck & Co., Inc. | $358.50B | $145.31 | — |
| NVS | NOVARTIS AG | $270.98B | $142.57 | — |
Recent Insider Activity
No insider activity indexed for this ticker.